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Interview Mansson
Flow has been approved in Europe as a medication-free treatment for depression. What are the problems with the current state-of-the-art for antidepressants? Antidepressant medication has helped many people live their lives without depression. More people should be encouraged to seek help for their depression -and consider all the options available, including antidepressants.
The problems that many people experience with antidepressants are the side effects. Typically, this means people stop using them -or the antidepressants cause new issues including sexual problems, weight gain or heightened anxiety. This poses a real problem for patients.
How does it work?
Flow consists of a brain stimulation headset and a therapy app which are used together as both have roles to play. The headset sends a gentle electrical signal. This excites neurons on the left frontal part of the head which rebalances neural activity in this area. And this is important as it has been shown that, in general, people with depression have less neural activity in the left frontal part of the brain.
During brain stimulation, the app teaches users what depression is and what can be done about it by changing lifestyle behavior in four areas: sleep, exercise, nutrition and meditation.
The headset is controlled by the app and is used for 30 min/day over a 6-week period. Treatment can continue one-to two-times per week after the 6-week period is over.
How has it fared in trials (please give a brief overview of results)?
tDCS has been studied since the early 1960s with an increasing amount of independent randomized controlled trials conducted over the last decades. There are 500+ articles published, each examining the effectiveness of tDCS and other electric brain stimulation techniques.
The area that we are most interested in is tDCS and depression. There are 10+ positive randomized controlled trials published in respected scientific journals, including the New England Journal of Medicine and British Journal of Psychiatry.
In a recent study published in New England Journal of Medicine, a double-blind placebo-controlled study showed that 41% of patients using tDCS experienced a 50% reduction or more in their depression. The effect of the antidepressant used in the study (escitalopram) was slightly higher than tDCS (47% of people experienced a 50% reduction in depression) [1] .
What's next?
This summer, Flow launched in the UK and Sweden. We will continue to improve the app and are opening up the treatment in other EU countries. Our collaboration with the scientific community is going from strength to strength. During late 2019, we are conducting a randomized controlled trial with professor Andre Brunoni (University of Sao Paolo, Brazil), one of the leading researchers in the field of tDCS and depression, and we have recently secured $1.5 million investment from Khosla Ventures for funding our European rollout and further clinical studies. We are also planning to launch Flow in several psychotherapy clinics in the UK. Our intention is that Flow will complement other techniques (such as talk therapy) used by psychotherapists in these clinics.
What's your dream for the future of treatment for depression?
Typically, people suffering with depression, particularly in the UK, have a long time to wait until treatment commences.
At Flow, we want to create a world where people have instant access to a diagnosis and subsequent treatment for their depression, without side effects. The WHO estimates that over 300 million people have depression, and have named the condition as the world's leading cause of disability. Flow, and other companies in this field, are continuing to advance technology to make tDCS treatment more efficient. We believe the path forward is personalization and this should be pursued with a great sense of urgency to ensure everyone can get access to treatment.
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